Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
| Autor: | Atsushi Kumanogoh, Yujiro Naito, Kentaro Masuhiro, Akio Osa, Shohei Koyama, Takashi Hirai |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
T-Lymphocytes
T cell medicine.medical_treatment General Chemical Engineering Programmed Cell Death 1 Receptor Pembrolizumab Pharmacology Antibodies Monoclonal Humanized General Biochemistry Genetics and Molecular Biology Blocking antibody medicine Humans Glucose test Antibodies Blocking medicine.diagnostic_test biology General Immunology and Microbiology business.industry General Neuroscience Immunotherapy Flow Cytometry Nivolumab medicine.anatomical_structure Monoclonal biology.protein Antibody business |
| Zdroj: | Journal of Visualized Experiments. |
| ISSN: | 1940-087X |
| DOI: | 10.3791/60608-v |
| Popis: | Immune checkpoint inhibitors, including PD-1-blocking antibodies, have significantly improved treatment outcomes in various types of cancer. The pharmacological efficacy of these immunotherapies is long lasting, extending even beyond the discontinuation of their injections, due to persistent blood concentrations. Here we developed a simple flow cytometry assay to evaluate the T cell binding status of the PD-1-blocking antibodies nivolumab and pembrolizumab. Like a glucose test, this assay requires just a single drop of peripheral blood. Visualizing antibody binding on T cells is more reliable than measuring antibody blood concentrations. In addition, if necessary, we can potentially analyze many distinctive immune-related markers on T cells bound to PD-1-blocking antibodies. Thus, this is a simple and minimally invasive strategy to analyze the pharmacological effect of PD-1-blocking antibodies in cancer patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|